| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NOG |
| Uniprot No | Q13253 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-232aa |
| 氨基酸序列 | QHYLHIRPAP SDNLPLVDLI EHPDPIFDPK EKDLNETLLR SLLGGHYDPG FMATSPPEDR PGGGGGAAGG AEDLAELDQL LRQRPSGAMP SEIKGLEFSE GLAQGKKQRL SKKLRRKLQM WLWSQTFCPV LYAWNDLGSR FWPRYVKVGS CFSKRSCSVP EGMVCKPSKS VHLTVLRWRC QRRGGQRCGW IPIQYPIISE CKCSC |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NOG重组蛋白的3篇参考文献及简要摘要：
---
1. **文献名称**：*"Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite"*
**作者**：McMahon, J.A., et al.
**摘要**：该研究通过体外重组NOG蛋白实验，揭示了其在胚胎发育中抑制BMP信号通路的关键作用，证明NOG通过拮抗BMP调控神经管和体节的分化与形态形成。
---
2. **文献名称**：*"Recombinant Noggin protein enhances neuronal differentiation of embryonic stem cells"*
**作者**：Gerrard, L., et al.
**摘要**：研究发现，添加重组NOG蛋白可抑制BMP信号，促进胚胎干细胞向神经元方向分化，为神经退行性疾病的细胞治疗提供了实验依据。
---
3. **文献名称**：*"Noggin regulates BMP signaling to orchestrate cartilage and bone morphogenesis"*
**作者**：Brunet, L.J., et al.
**摘要**：通过重组NOG蛋白的体内外实验，阐明其在骨骼发育中动态调节BMP活性的机制，证明NOG缺失会导致骨骼畸形，提示其在骨骼疾病中的潜在治疗价值。
---
以上文献涵盖NOG重组蛋白在胚胎发育、干细胞分化及骨骼疾病中的功能研究。如需具体文章年份或期刊，可进一步补充检索关键词(如“recombinant Noggin BMP signaling”)。
Noggin (NOG) is a secreted glycoprotein that plays a critical role in embryonic development, particularly in neural tube formation, skeletal morphogenesis, and joint specification. It functions as a key antagonist of bone morphogenetic proteins (BMPs), binding directly to BMP ligands (e.g., BMP-2. BMP-4. BMP-7) to inhibit their interaction with cell surface receptors. This inhibition modulates BMP signaling pathways, which are essential for regulating cell differentiation, tissue patterning, and organogenesis.
Recombinant NOG protein is produced using biotechnological methods, such as expression in Escherichia coli or mammalian cell lines, followed by purification to ensure bioactivity. Its ability to suppress BMP signaling has made it a valuable tool in developmental biology research, stem cell studies, and regenerative medicine. For instance, NOG is used to maintain pluripotency in embryonic stem cells by blocking BMP-induced differentiation. It also shows therapeutic potential in conditions involving excessive BMP activity, such as fibrodysplasia ossificans progressiva (FOP), or in promoting cartilage repair and neuroprotection.
Studies have further explored NOG's role in cancer, where dysregulated BMP signaling contributes to tumor progression. Additionally, recombinant NOG is employed in vitro to model developmental processes or optimize differentiation protocols for tissue engineering. Despite its promise, challenges remain in delivery methods and stability for clinical applications. Ongoing research aims to refine NOG-based therapies and elucidate its broader molecular interactions, underscoring its significance as both a biological regulator and a biomedical reagent.
×
